| Budget Amount *help |
¥43,290,000 (Direct Cost: ¥33,300,000、Indirect Cost: ¥9,990,000)
Fiscal Year 2019: ¥10,530,000 (Direct Cost: ¥8,100,000、Indirect Cost: ¥2,430,000)
Fiscal Year 2018: ¥10,790,000 (Direct Cost: ¥8,300,000、Indirect Cost: ¥2,490,000)
Fiscal Year 2017: ¥10,790,000 (Direct Cost: ¥8,300,000、Indirect Cost: ¥2,490,000)
Fiscal Year 2016: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
|
|---|
| Outline of Final Research Achievements |
In the development of DDS, the molecular mechanism of off-target effects has not been discussed enough. This project aims to establish an evaluation system for DDS based on analytical science, informatics, and genomics/proteomics analysis. Transcriptional factors were selected by analyzing databases of drug-induced liver injury and transcriptional factor binding sites. In addition, three proteins with a significant variation in phosphorylation in the liver after administration of DDS formulation were identified by LC/MS/MS. Based on the combinatory analysis of these data, we established CREB reporter assay system and evaluated DDS formulation by the system.
|
